Hvsen Biotechnology Co. Ltd. Class A

Hvsen Biotechnology Co. Ltd. Class A

SSZSE:300871
18.93
CNY
+0.56
(+3.05%)
1.55EPS
13.11P/E
4.26BMarket Cap
Apr 29Next Earn

Total Valuation

CNY

As of September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A carries a market capitalization of 4.26B, placing it among publicly traded companies globally. Its enterprise value stands at 4.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap4.26B
Enterprise Value4.31B

Important Dates

Hvsen Biotechnology Co. Ltd. Class A's next confirmed earnings release is scheduled for April 29, 2027.

Earnings Date4/29/2027

Share Statistics

As of September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A has 201.78M shares outstanding.

Shares Outstanding201.78M

Valuation Ratios

As of September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A trades at a trailing price-to-earnings ratio of 13.11. The price-to-sales ratio is 2.49, and the price-to-book ratio stands at 1.85.

PE Ratio13.11
PS Ratio2.49
PB Ratio1.85
P/TBV Ratio1.94

Enterprise Valuation

As of September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A trades at an EV/EBITDA multiple of 11.76 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.53 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 11.76 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 4.31B versus a market cap of 4.26B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.53
EV / EBITDA11.76
EV / EBIT11.76

Financial Position

As of September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A maintains a current ratio of 2.09, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 22.22, indicating elevated leverage, while an interest coverage ratio of 115.81 demonstrates strong ability to service its debt obligations.

Current Ratio2.09
Quick Ratio0.71
Debt / Equity22.22
Debt / EBITDA1.41
Interest Coverage115.81

Financial Efficiency

CNY

Over the twelve months ended September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A posted a return on equity (ROE) of 14.85, showing how much profit the company earns on every dollar of shareholder capital. Return on invested capital (ROIC) comes in at 12.31 - the clearest signal of whether the business earns more on its capital than that capital costs, and the core measure of a durable competitive advantage. Return on assets (ROA) stands at 10.18, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 12.41, useful for judging operating efficiency across full business cycles. The company generates approximately 1.51M in revenue per employee across its workforce of 1,133.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 4.03 indicates how many times Hvsen Biotechnology Co. Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)14.85
Return on Assets (ROA)10.18
Return on Invested Capital (ROIC)12.31
Return on Capital Employed (ROCE)12.41
Revenue Per Employee1.51M
Employee Count1,133.00
Inventory Turnover4.03

Taxes

CNY

Over the twelve months ended September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A recorded 41.19M in income tax expense. That works out to an effective tax rate of 11.25, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 366.29M, leaving 324.09M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax41.19M
Effective Tax Rate11.25

Stock Price Statistics

CNY

As of the close on November 17, 2026, Hvsen Biotechnology Co. Ltd. Class A's stock has declined approximately 13.84% over the past 52 weeks. The 50-day moving average sits at 19.77, while the 200-day moving average is 23.25.

52-Week Price Change-13.84%
50-Day Moving Average19.77
200-Day Moving Average23.25

Income Statement

CNY

Over the twelve months ended September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A generated 1.71B in revenue and converted that into 324.09M in net income, yielding earnings per share of 1.55. EBITDA reached 366.31M, while operating income came in at 324.60M.

Revenue1.71B
Gross Profit583.74M
Operating Income324.60M
Pretax Income366.29M
Net Income324.09M
EBITDA366.31M
EBIT366.31M
Earnings Per Share (EPS)1.55

Balance Sheet

CNY

As of September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A holds 476.83M in cash and equivalents against 515.40M in total debt, resulting in a net debt position of 212.60M. Total book value stands at 2.31B, with working capital of 728.75M providing operational flexibility.

Cash & Cash Equivalents476.83M
Total Debt515.40M
Net Debt212.60M
Equity (Book Value)2.31B
Book Value Per Share11.43
Working Capital728.75M

Cash Flow

CNY

These figures cover the twelve months ended September 30, 2026.

Capital Expenditures-419.83M

Margins

Over the twelve months ended September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A posted a gross margin of 34.21, reflecting its pricing power and cost economics. The operating margin of 19.02 and net profit margin of 18.99 provide insight into operational efficiency.

Gross Margin34.21
Operating Margin19.02
Pretax Margin21.47
Profit Margin18.99
EBITDA Margin21.47

Dividends & Yields

CNY

Over the twelve months ended September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A paid dividends of 0.53 per share. The dividend payout ratio of 32.78 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield is negative at -1.75, meaning Hvsen Biotechnology Co. Ltd. Class A raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Dividend Per Share0.53
Payout Ratio32.78
Shareholder Yield-1.75

Stock Splits

Hvsen Biotechnology Co. Ltd. Class A's most recent stock split took place on May 10, 2021 with a 2:3 split ratio.

Last Split Date5/10/2021
Split Ratio2:3

Scores

As of September 30, 2026, Hvsen Biotechnology Co. Ltd. Class A has an Altman Z-Score of 3.74, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score3.74